Hemerus Medical

What Hemerus Medical does

Hemerus Medical, LLC is a privately held, Minnesota-based medical device company founded in 2001 that designs, develops, and manufactures blood collection, processing, preservation, and storage technologies for the transfusion medicine market. Its product platform centers on the SOLX™ (AS-7) System—an FDA-approved, CE-marked additive solution and processing system for preparing red blood cells, leukocyte-reduced components, and plasma from CPD whole blood held up to 24 hours at room temperature, with indications for up to 42 days of storage in the US and 56 days under CE marking. The portfolio is complemented by LEUKOWEB™ leukocyte reduction media, LEUKOSEP™ leukocyte reduction filters, LEUP™ processing circuits, and next-generation additive solutions (SOLX+™, APEX™, APEX+™), supported by patents issued in January 2025 covering DEHP-free blood collection and storage systems.

The company's business model is a hardware and consumable sales motion targeting blood banks, transfusion centers, and hospital systems through direct enterprise field sales. Hemerus is currently pre-commercial: the SOLX™ System is not available for sale, with market introduction planned for October 2026, and pricing has not been publicly disclosed. The company operates with a small team of 1-10 employees from its headquarters at 5000 Township Parkway, Saint Paul, MN, and reports no disclosed funding rounds, partnerships, or acquisition activity in the available data. Strategic positioning has emphasized regulatory differentiation (CE marking, FDA approval for unique room-temperature whole blood processing claims) and ESG-aligned product design through the DEHP-free initiative announced in June 2024.

Name

Hemerus Medical

Legal name

Hemerus Medical, LLC

Website

https://hemerus.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

1–10 employees

Short description

Hemerus Medical, LLC is a Saint Paul-based medical device company developing FDA-approved and CE-marked blood collection, processing, and storage technologies, including the SOLX™ (AS-7) System, for sale to US blood banks, transfusion centers, and hospitals.

Ownership category

akta.pro rank

Headquarters

HQ city

Saint Paul

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales

Revenue model

1. Medical Device Sales: Pre-commercial stage. The company is developing and preparing to commercialize its SOLX™ System and related blood collection and storage technologies for healthcare facilities including blood banks and hospitals. Market introduction expected October 2026.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Hemerus Medical designs, develops, and manufactures blood collection, processing, preservation, and storage technologies used in transfusion medicine. Its flagship SOLX™ (AS-7) System is an FDA-approved blood collection and processing system with anticoagulant and additive solution supporting up to 42-day red blood cell storage in the U.S. The portfolio also includes leukocyte reduction products (LEUKOWEB™, LEUKOSEP™), processing circuits (LEUP™), and next-generation additive solutions (SOLX+™, APEX™, APEX+™).

Product overview

Hemerus Medical offers a platform of blood collection, processing, preservation, and storage technologies. The portfolio centers on the SOLX™ (AS-7) System as the core technology, complemented by leukocyte reduction products (LEUKOWEB™, LEUKOSEP™), processing circuits (LEUP™), and next-generation additive solutions (SOLX+™, APEX™, APEX+™) for red blood cells and whole blood. The SOLX™ System is the first and only 56-day liquid red cell storage solution with CE marking (currently 42 days in the US) and the first and only manual collection system approved for preparation of plasma from whole blood held up to 24 hours at room temperature in the United States.

Differentiator

Problem solved

Functional benefit

Brands

• SOLX: SOLX Solution (AS-7) - Red blood cell additive solution and the SOLX System for blood collection and processing.
• LEUKOWEB
• LEUKOSEP
• LEUP
• APEX
• APEX+

Products and services

• SOLX™ (AS-7) System FDA-approved blood collection and processing system with CPD anticoagulant and AS-7 additive solution for leukoreduction of whole blood and preparation of red blood cells and plasma. Supports up to 42-day RBC storage and one-year frozen plasma storage. Targets blood banks, transfusion centers, and hospitals.
• SOLX™ Solution (AS-7) Red blood cell additive solution; the only RBC additive solution approved in the U.S. for preparation of RBCs from whole blood held at room temperature for up to 24 hours.
• SOLX+™ Solution Next-generation additive solution for red blood cells; part of the SOLX™ platform technology for extended storage and preservation.
• APEX™ Solution Next-generation additive solution for whole blood processing and preservation.
• APEX+™ Solution Next-generation enhanced additive solution for whole blood processing and preservation.
• LEUKOWEB™ Leukocyte reduction media designed to effectively remove leukocytes from blood and blood products during processing.
• LEUKOSEP™ Self-priming leukocyte reduction filters providing high-efficiency leukoreduction with low residual hold-up for rapid and effortless filtration of blood products.
• LEUP™ Processing Circuits Leukoreduction processing circuit technology enabling vent-free, one-step filtration of blood products, improving efficiency and freeing operator labor.

Quantifiable outcome

• 56-day red blood cell storage capability (with CE marking)
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Direct peers

• Terumo BCT: Terumo BCT is one of the largest suppliers of blood collection, processing, and storage systems globally, with automated component processing platforms and manual collection sets. Its portfolio directly overlaps Hemerus's whole-blood collection, leukoreduction, and RBC additive solution categories.
• Immucor: Immucor (now part of IVD Holdings) is a leading provider of transfusion and transplantation diagnostics, including immunohematology reagents and blood-bank instruments. It is a relevant peer in the blood-bank customer channel served by Hemerus, although its core focus is pre-transfusion testing rather than collection/storage.
• Haemonetics Corporation: Haemonetics is a global leader in blood component processing, including whole blood collection sets, leukoreduction filters, and automated component processing systems. It is the closest direct competitor to Hemerus's SOLX System, LEUP circuits, and LEUKOSEP filters in the blood-center channel.
• Fresenius Kabi (Fenwal): Fresenius Kabi, following its acquisition of Fenwal, supplies blood collection sets, component processing systems, and storage solutions to blood centers and hospitals. It is a direct competitor in collection sets, processing circuits, and additive solutions overlapping Hemerus's portfolio.
• Macopharma: Macopharma is a French medical device company specializing in blood collection systems, leukocyte reduction filters, and transfusion safety products. It directly competes with Hemerus's LEUKOSEP filters, LEUP circuits, and SOLX collection/storage sets in blood centers worldwide.

Broad incumbents

• Bio-Rad Laboratories: Bio-Rad is a major supplier of blood-bank quality controls, immunohematology reagents, and transfusion-medicine diagnostics, serving the same blood-center and hospital customers as Hemerus. While a broader life-science tools company, its blood-bank business directly overlaps with Hemerus's customer base.
• Grifols: Grifols is a global plasma-derived therapeutics leader with a significant blood-collection and blood-typing diagnostics business. While its center of gravity is plasma fractionation, its blood-bank and transfusion-medicine products (including collection sets and IVD reagents) overlap with Hemerus's downstream customers.
• Ortho Clinical Diagnostics: Ortho Clinical Diagnostics (a QuidelOrtho company) is a major provider of immunohematology and blood-bank screening products used in transfusion medicine. It is a broad incumbent serving the same blood-center and hospital transfusion customers as Hemerus, though with diagnostic rather than collection devices.

Emerging players

• Cerus Corporation: Cerus develops INTERCEPT, a pathogen reduction system for blood components, which addresses adjacent quality and safety concerns in transfusion medicine. It is an emerging competitor in the blood-center workflow where Hemerus's SOLX System is also positioned, but with a different technology approach.
• AdvaCare Pharma: AdvaCare Pharma is a manufacturer and distributor of medical consumables including blood collection bags and IV administration sets, with operations across emerging markets. It is an emerging player in blood collection devices that competes with Hemerus's manual collection sets in cost-sensitive geographies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/hemerus-medical-llc

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hemerus Medical